Vironova leads a new Influenza drug development program with EU funding of 6M Euros

STOCKHOLM – 22 february, 2011 – Vironova today announces Grant funding of 6MEuros to support influenza drug development.

Vironova is pleased to announce the successful completion of negotiations with the European Commission to co-finance an influenza drug development programme. The “FLUCURE” project received the highest ranking of the funding bid that was submitted to the European Commission´s Seventh Framework programme in competition with proposals from influenza scientists and companies around Europe.

The project, which is headed by Vironova, is a collaboration between 9 top European industry and academic partners (in Stockholm, Uppsala, Zurich, Amsterdam, Sofia, Freiburg, Saarbrücken, Siena, Vilnius).

“This is a very exciting project” said Vironova´s CEO, Mohammed Homman. “Antiviral drug discovery and development is a key business area for our company, and the FLUCURE project is a welcome addition to Vironova´s drug development portfolio. This is a unique opportunity to work with some of Europe´s top scientists experts to develop new drug candidates in the fight against influenza virus infection”

Vironova is the coordinator of the project, which will run from 2010-2014.

Contact

For further information please contact: Mr Mohammed Homman, CEO or Dr Heather Marshall-Heyman, FLUCURE Coordinator. Tel: +46 (0)8- 702 67 90